Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Shibuya, Kendall C ^a   Goel, Vikas K ^c   Xiong, Wei ^b,e   Sham, Jonathan G ^c   Pollack, Seth M ^a,b   Leahy, Allison M ^d   Whiting, Samuel H ^b   Yeh, Matthew M ^b   Yee, Cassian ^a,b   Riddell, Stanley R ^a,b   Pillarisetty, Venu G ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Section of Surgical Oncology   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CD11B ANTIGEN; DOCETAXEL; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; OXALIPLATIN; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL ISOLATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HELPER CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREGULATION; INFLAMMATORY CELL; MALE; MEMORY T LYMPHOCYTE; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT; VERY ELDERLY; ADENOCARCINOMA; ADJUVANT THERAPY; CARCINOMA, PANCREATIC DUCTAL; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; PANCREAS; PATHOLOGY; PROCEDURES;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREAS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84900420880     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096565     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62: 10-29. doi:10.3322/caac.20138.
2. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, et al. (2013) Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 108: 914-923. doi:10.1038/bjc.2013.32.
3. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, et al. (2013) Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 20: 946-955. doi:10.1245/s10434-012-2668-9.
4. Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, et al. (2009) Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. PLoS ONE 4: e6412. doi:10.1371/journal.pone.0006412.t003.
5. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483. doi:10.1016/j.ccr.2005.04.023. (Pubitemid 40719130)
6. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, et al. (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67: 9518-9527. doi:10.1158/0008-5472.CAN-07-0175. (Pubitemid 47535942)
7. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, et al. (2011) CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans. Science 331: 1612-1616. doi:10.1126/science. 1198443.
8. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, et al. (2012) Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer. Cancer Cell 21: 822-835. doi:10.1016/j.ccr.2012.04.025.
9. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D (2012) Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia. Cancer Cell 21: 836-847. doi:10.1016/j.ccr.2012.04.024.
10. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117. doi:10.1038/nature09515.
11. Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12: 5423-5434. doi:10.1158/1078-0432.CCR-06-0369. (Pubitemid 44497257)
12. Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, et al. (2006) Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother 29: 416-424. doi:10.1097/01.cji.0000205644.43735. 4e. (Pubitemid 44288954)
13. Hinz S, Pagerols-Raluy L, Oberg H-H, Ammerpohl O, Grüssel S, et al. (2007) Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67: 8344-8350. doi:10.1158/0008-5472.CAN- 06-3304. (Pubitemid 47395173)
14. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, et al. (2011) Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 167: e211-e219. doi:10.1016/j.jss.2009.05.026.
15. Porembka MR, Mitchem JB, Belt BA, Hsieh C-S, Lee H-M, et al. (2012) Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. doi:10.1007/s00262-011-1178-0.
16. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW (2011) Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 60: 1419-1430. doi:10.1007/s00262-011-1028-0.
17. Ikemoto T, Yamaguchi T, Morine Y, Imura S, Soejima Y, et al. (2006) Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 33: 386-390. doi:10.1097/01.mpa.0000240275.68279.13. (Pubitemid 44690729)
18. He S, Fei M, Wu Y, Zheng D, Wan D, et al. (2011) Distribution and clinical significance of th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci 12: 7424-7437. doi:10.3390/ijms12117424.
19. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, et al. (2007) Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178: 6730-6733. (Pubitemid 46847396)
20. Ryschich E, Nötzel T, Hinz U, Autschbach F, Ferguson J, et al. (2005) Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 11: 498-504. Available: http://clincancerres.aacrjournals.org/content/11/2/498.full.
21. Schmitz-Winnenthal FH, Volk C, Z'graggen K, Galindo L, Nummer D, et al. (2005) High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 65: 10079-10087. doi:10.1158/0008-5472.CAN-05-1098. (Pubitemid 41541490)
22. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, et al. (2004) CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28: e26-e31.
23. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med 366: 2443-2454. doi:10.1056/NEJMoa1200690.
24. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, et al. (2012) Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med 366: 2455-2465. doi:10.1056/NEJMoa1200694.
25. Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, et al. (2008) The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 61: 167-175. doi:10.1007/s00280-007-0473-0. (Pubitemid 47512638)
26. Crippa S, Partelli S, Zamboni G, Barugola G, Capelli P, et al. (2012) Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile? Surgery 152: S112-S119. doi:10.1016/j.surg.2012.05.017.
27. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, et al. (2000) Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191: 1499-1512. (Pubitemid 30257347)
28. Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, et al. (2012) Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS ONE 7: e42274. doi:10.1371/journal.pone. 0042274.
29. He D, Li H, Yusuf N, Elmets CA, Li J, et al. (2010) IL-17 Promotes Tumor Development through the Induction of Tumor Promoting Microenvironments at Tumor Sites and Myeloid-Derived Suppressor Cells. The Journal of Immunology 184: 2281-2288. doi:10.4049/jimmunol.0902574.
30. Gnerlich JL, Mitchem JB, Weir JS, Sankpal NV, Kashiwagi H, et al. (2010) Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. The Journal of Immunology 185: 4063-4071. doi:10.4049/jimmunol.0902609.
31. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114: 357-359. doi:10.1182/blood-2008-09-177360.
32. Geng L, Huang D, Liu J, Qian Y, Deng J, et al. (2008) B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol 134: 1021-1027. doi:10.1007/s00432-008- 0364-8.
33. Plate JMD, Plate AE, Shott S, Bograd S, Harris JE (2005) Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54: 915-925. doi:10.1007/s00262-004-0638-1. (Pubitemid 40991334)
34. Homma Y, Taniguchi K, Nakazawa M, Matsuyama R, Mori R, et al. (2013) Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. Clin Transl Oncol. doi:10.1007/s12094-013-1079-0.
35. Vonderheide RH, Bayne LJ (2013) Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol. doi:10.1016/j.coi.2013. 01.006.
36. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, et al. (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13: 2151-2157. doi:10.1158/1078-0432.CCR-06-2746. (Pubitemid 46649885)
37. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, et al. (2013) Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. Cancer Res 73: 1733-1741. doi:10.1158/0008-5472.CAN-12-2384.
38. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, et al. (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. Journal of Experimental Medicine 207: 2187-2194. doi:10.1038/nri1936.
39. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-133. doi:10.1056/NEJMoa1302369.
40. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7: e1000267. doi:10.1371/journal.pmed.1000267.
41. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, et al. (2012) Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148: 362-375. doi:10.1016/j.cell.2011.11.060.
42. Garnett CT, Schlom J, Hodge JW (2008) Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 14: 3536-3544. doi:10.1158/1078-0432.CCR-07-4025.
43. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, et al. (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70: 3052-3061. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=20388795.